Qing Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Qing Lin has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Yiyue Zhang
Division of Cell, Developmental and Integrative Biology, School of Medicine, South China University of Technology, Guangzhou, China
11 shared publications Panpan Meng
Cancer Center, School of Medicine, the Sixth Affiliated Hospital of South China University of Technology (Nanhai District People's Hospital of Foshan), Foshan, 528200, China
6 shared publicationsJiajun Chen
The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, 510006, China
3 shared publicationsJiaye Wu
Division of Cell, Developmental and Integrative Biology, School of Medicine, South China University of Technology, Guangzhou, China
3 shared publicationsYiming Ling
The Sixth Affiliated Hospital / Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, China
3 shared publicationsYing Sun
Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Guangdong Higher Education Institutes, Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
3 shared publications
Latest Publications
- 13 October 2026
- Published by Elsevier in Differentiation
- Vol. 152, 101004
Comparative transcriptomics identifies conserved gene signatures defining megakaryocyte development states across species
- 13 October 2026
- Published by Elsevier in Differentiation
- Vol. 152, 101004
Comparative transcriptomics identifies conserved gene signatures defining megakaryocyte development states across species
- 7 September 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (11) , 3908-3924
An inducible zebrafish model of thrombocytopenia enables in vivo drug screening and reveals fibroblast growth factor signaling as a key regulator of platelet regeneration
- 7 September 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (11) , 3908-3924
An inducible zebrafish model of thrombocytopenia enables in vivo drug screening and reveals fibroblast growth factor signaling as a key regulator of platelet regeneration
- Open Access
- 22 December 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1)
Minoxidil ameliorates myelodysplastic syndrome by targeting Wnt4 while sparing normal hematopoiesis
Hematopoietic stem cells (HSCs) maintain blood production via tightly regulated differentiation. Disruptions at this level can lead to myelodysplastic synd
- 22 December 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1)
Open AccessMinoxidil ameliorates myelodysplastic syndrome by targeting Wnt4 while sparing normal hematopoiesis
Hematopoietic stem cells (HSCs) maintain blood production via tightly regulated differentiation. Disruptions at this level can lead to myelodysplastic synd
- Open Access
- 11 February 2025
- Published by Wolters Kluwer Health in Blood Science
- Vol. 7 (1) , e00216
Decitabine facilitates thrombopoiesis independent of the thrombopoietin receptor in zebrafish
- 11 February 2025
- Published by Wolters Kluwer Health in Blood Science
- Vol. 7 (1) , e00216
Open AccessDecitabine facilitates thrombopoiesis independent of the thrombopoietin receptor in zebrafish
- 20 September 2024
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 22 (12) , 3599-3613
Paclitaxel improves thrombopoiesis in the absence of thrombopoietin receptor (Mpl)
- 20 September 2024
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 22 (12) , 3599-3613
Paclitaxel improves thrombopoiesis in the absence of thrombopoietin receptor (Mpl)
- 24 June 2024
- Published by Elsevier in Journal of Genetics and Genomics
- Vol. 51 (9) , 970-973
Assessing the efficacy and safety of gemcitabine-induced thrombocytopenia/neutropenia and thrombocytopenia interventions in zebrafish
- 24 June 2024
- Published by Elsevier in Journal of Genetics and Genomics
- Vol. 51 (9) , 970-973
Assessing the efficacy and safety of gemcitabine-induced thrombocytopenia/neutropenia and thrombocytopenia interventions in zebrafish
- Open Access
- 13 May 2024
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 31 (1) , 1-17
Somatic PDGFRB activating variants promote smooth muscle cell phenotype modulation in intracranial fusiform aneurysm
Background: The fusiform aneurysm is a nonsaccular dilatation affecting the entire vessel wall over a short distance. Although PDGFRB somatic variants have been identified in fusiform intracranial aneurysms, the molecular and cellular mechanisms driving fusiform intracranial aneurysms due to PDGFRB somatic variants remain poorly understood. Methods: In this study, single-cell sequencing and immunofluorescence were employed to investigate the phenotypic changes in smooth muscle cells within fusiform intracranial aneurysms. Whole-exome sequencing revealed the presence of PDGFRB gene mutations in fusiform intracranial aneurysms. Subsequent immunoprecipitation experiments further explored the functional alterations of these mutated PDGFRB proteins. For the common c.1684 mutation site of PDGFRβ, we established mutant smooth muscle cell lines and zebrafish models. These models allowed us to simulate the effects of PDGFRB mutations. We explored the major downstream cellular pathways affected by PDGFRBY562D mutations and evaluated the potential therapeutic effects of Ruxolitinib. Results: Single-cell sequencing of two fusiform intracranial aneurysms sample revealed downregulated smooth muscle cell markers and overexpression of inflammation-related markers in vascular smooth muscle cells, which was validated by immunofluorescence staining, indicating smooth muscle cell phenotype modulation is involved in fusiform aneurysm. Whole-exome sequencing was performed on seven intracranial aneurysms (six fusiform and one saccular) and PDGFRB somatic mutations were detected in four fusiform aneurysms. Laser microdissection and Sanger sequencing results indicated that the PDGFRB mutations were present in smooth muscle layer. For the c.1684 (chr5: 149505131) site mutation reported many times, further cell experiments showed that PDGFRBY562D mutations promoted inflammatory-related vascular smooth muscle cell phenotype and JAK-STAT pathway played a crucial role in the process. Notably, transfection of PDGFRBY562D in zebrafish embryos resulted in cerebral vascular anomalies. Ruxolitinib, the JAK inhibitor, could reversed the smooth muscle cells phenotype modulation in vitro and inhibit the vascular anomalies in zebrafish induced by PDGFRB mutation. Conclusion: Our findings suggested that PDGFRB somatic variants played a role in regulating smooth muscle cells phenotype modulation in fusiform aneurysms and offered a potential therapeutic option for fusiform aneurysms.
- 13 May 2024
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 31 (1) , 1-17
Open AccessSomatic PDGFRB activating variants promote smooth muscle cell phenotype modulation in intracranial fusiform aneurysm
Background: The fusiform aneurysm is a nonsaccular dilatation affecting the entire vessel wall over a short distance. Although PDGFRB somatic variants have been identified in fusiform intracranial aneurysms, the molecular and cellular mechanisms driving fusiform intracranial aneurysms due to PDGFRB somatic variants remain poorly understood. Methods: In this study, single-cell sequencing and immunofluorescence were employed to investigate the phenotypic changes in smooth muscle cells within fusiform intracranial aneurysms. Whole-exome sequencing revealed the presence of PDGFRB gene mutations in fusiform intracranial aneurysms. Subsequent immunoprecipitation experiments further explored the functional alterations of these mutated PDGFRB proteins. For the common c.1684 mutation site of PDGFRβ, we established mutant smooth muscle cell lines and zebrafish models. These models allowed us to simulate the effects of PDGFRB mutations. We explored the major downstream cellular pathways affected by PDGFRBY562D mutations and evaluated the potential therapeutic effects of Ruxolitinib. Results: Single-cell sequencing of two fusiform intracranial aneurysms sample revealed downregulated smooth muscle cell markers and overexpression of inflammation-related markers in vascular smooth muscle cells, which was validated by immunofluorescence staining, indicating smooth muscle cell phenotype modulation is involved in fusiform aneurysm. Whole-exome sequencing was performed on seven intracranial aneurysms (six fusiform and one saccular) and PDGFRB somatic mutations were detected in four fusiform aneurysms. Laser microdissection and Sanger sequencing results indicated that the PDGFRB mutations were present in smooth muscle layer. For the c.1684 (chr5: 149505131) site mutation reported many times, further cell experiments showed that PDGFRBY562D mutations promoted inflammatory-related vascular smooth muscle cell phenotype and JAK-STAT pathway played a crucial role in the process. Notably, transfection of PDGFRBY562D in zebrafish embryos resulted in cerebral vascular anomalies. Ruxolitinib, the JAK inhibitor, could reversed the smooth muscle cells phenotype modulation in vitro and inhibit the vascular anomalies in zebrafish induced by PDGFRB mutation. Conclusion: Our findings suggested that PDGFRB somatic variants played a role in regulating smooth muscle cells phenotype modulation in fusiform aneurysms and offered a potential therapeutic option for fusiform aneurysms.
- 7 March 2024
- Published by Wiley in Developmental Dynamics
- Vol. 253 (10) , 906-921
Establishment of a Diamond‐Blackfan anemia like model in zebrafish
Background: Anemia is defined as a lack of erythrocytes, low hemoglobin levels, or abnormal erythrocyte morphology. Diamond‐Blackfan anemia (DBA) is a rare and severe congenital hypoplastic anemia that occurs due to the dominant inheritance of a ribosomal protein gene mutation. Even rarer is a case described as Diamond‐Blackfan anemia like (DBAL), which occurs due to a loss‐of‐function EPO mutation recessive inheritance. The effective cures for DBAL are bone marrow transfusion and treatment with erythropoiesis‐stimulating agents (ESAs). To effectively manage the condition, construction of DBAL models to identify new medical methods or screen drugs are necessary.Results: Here, an epoa‐deficient mutant zebrafish called epoaszy8 was generated to model DBAL. The epoa‐deficiency in zebrafish caused developmental defects in erythroid cells, leading to severe congenital anemia. Using the DBAL model, we validated a loss‐of‐function EPO mutation using an in vivo functional analysis and explored the ability of ESAs to alleviate congenital anemia.Conclusions: Together, our study demonstrated that epoa deficiency in zebrafish leads to a phenotype resembling DBAL. The DBAL zebrafish model was found to be beneficial for the in vivo assessment of patient‐derived EPO variants with unclear implications and for devising potential therapeutic approaches for DBAL.
- 7 March 2024
- Published by Wiley in Developmental Dynamics
- Vol. 253 (10) , 906-921
Establishment of a Diamond‐Blackfan anemia like model in zebrafish
Background: Anemia is defined as a lack of erythrocytes, low hemoglobin levels, or abnormal erythrocyte morphology. Diamond‐Blackfan anemia (DBA) is a rare and severe congenital hypoplastic anemia that occurs due to the dominant inheritance of a ribosomal protein gene mutation. Even rarer is a case described as Diamond‐Blackfan anemia like (DBAL), which occurs due to a loss‐of‐function EPO mutation recessive inheritance. The effective cures for DBAL are bone marrow transfusion and treatment with erythropoiesis‐stimulating agents (ESAs). To effectively manage the condition, construction of DBAL models to identify new medical methods or screen drugs are necessary.Results: Here, an epoa‐deficient mutant zebrafish called epoaszy8 was generated to model DBAL. The epoa‐deficiency in zebrafish caused developmental defects in erythroid cells, leading to severe congenital anemia. Using the DBAL model, we validated a loss‐of‐function EPO mutation using an in vivo functional analysis and explored the ability of ESAs to alleviate congenital anemia.Conclusions: Together, our study demonstrated that epoa deficiency in zebrafish leads to a phenotype resembling DBAL. The DBAL zebrafish model was found to be beneficial for the in vivo assessment of patient‐derived EPO variants with unclear implications and for devising potential therapeutic approaches for DBAL.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 14
Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia
Platelets, derived from a certain subpopulation of megakaryocytes, are closely related to hemostasis, coagulation, metastasis, inflammation, and cancer progression. Thrombopoiesis is a dynamic process regulated by various signaling pathways in which thrombopoietin (THPO)–MPL is dominant. Thrombopoiesis-stimulating agents could promote platelet production, showing therapeutic effects in different kinds of thrombocytopenia. Some thrombopoiesis-stimulating agents are currently used in clinical practices to treat thrombocytopenia. The others are not in clinical investigations to deal with thrombocytopenia but have potential in thrombopoiesis. Their potential values in thrombocytopenia treatment should be highly regarded. Novel drug screening models and drug repurposing research have found many new agents and yielded promising outcomes in preclinical or clinical studies. This review will briefly introduce thrombopoiesis-stimulating agents currently or potentially valuable in thrombocytopenia treatment and summarize the possible mechanisms and therapeutic effects, which may enrich the pharmacological armamentarium for the medical treatment of thrombocytopenia.
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 14
Open AccessApplication and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia
Platelets, derived from a certain subpopulation of megakaryocytes, are closely related to hemostasis, coagulation, metastasis, inflammation, and cancer progression. Thrombopoiesis is a dynamic process regulated by various signaling pathways in which thrombopoietin (THPO)–MPL is dominant. Thrombopoiesis-stimulating agents could promote platelet production, showing therapeutic effects in different kinds of thrombocytopenia. Some thrombopoiesis-stimulating agents are currently used in clinical practices to treat thrombocytopenia. The others are not in clinical investigations to deal with thrombocytopenia but have potential in thrombopoiesis. Their potential values in thrombocytopenia treatment should be highly regarded. Novel drug screening models and drug repurposing research have found many new agents and yielded promising outcomes in preclinical or clinical studies. This review will briefly introduce thrombopoiesis-stimulating agents currently or potentially valuable in thrombocytopenia treatment and summarize the possible mechanisms and therapeutic effects, which may enrich the pharmacological armamentarium for the medical treatment of thrombocytopenia.
- 27 May 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (8) , 1900-1909
Generation of a thrombopoietin‐deficient thrombocytopenia model in zebrafish
- 27 May 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (8) , 1900-1909
Generation of a thrombopoietin‐deficient thrombocytopenia model in zebrafish